To support the advanced development of candidate therapeutics for biodefense pathogens or emerging infectious diseases. The supported research and development activities will progress the therapeutic product development and may include lead optimization, candidate selection, preclinical and IND enabling studies, Chemistry, Manufacturing, and Controls (CMC), IND submission, clinical safety and efficacy assessment. Efforts include a Phase II clinical trial.